Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590535 · ClinicalTrials.gov registry record
5th Generation cTnT in ED ACS
A clinical trial of Acute Coronary Syndrome, sponsored by Columbia University.
- Completed
- Registry status
- 1,949
- Enrollment target
- 1
- Study location
NCT03590535: Completed study of Acute Coronary Syndrome, sponsored by Columbia University.
NCT03590535 is a study of Acute Coronary Syndrome that has completed, run by Columbia University. The registered enrollment target is 1,949 participants, below the 2,673-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03590535, a study of Acute Coronary Syndrome, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 1,949 participants
- Enrollment target
- 1
- Study location
Study Summary
This study intends to investigate the usefulness of the new "5th generation" cardiac troponin enzyme in determining which patients presenting with possible acute coronary syndrome can be quickly and safely discharged or admitted from the Emergency Department. The investigators hypothesize that introducing this enzyme into practice will reduce the time it takes to make decisions about admitting or discharging these patients with no increase in adverse events in the discharged patients.
Primary Outcome
Time in minutes from initial provider contact in the Emergency Department to disposition (admission versus discharge) decision.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 4th Gen cTnT
- DIAGNOSTIC_TEST 5th Gen cTnT
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,949 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2020-06-07 |
What the finished NCT03590535 record still lists
NCT03590535 is an observational study that tracks outcomes without assigning an intervention. Its 1,949 participants enrollment target places it among the larger protocols in the corpus, below the 2,673-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which 4th Gen cTnT is the first listed.
NCT03590535 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03590535 about?
NCT03590535 is a clinical study titled "5th Generation cTnT in ED ACS". This study intends to investigate the usefulness of the new "5th generation" cardiac troponin enzyme in determining which patients presenting with possible acute coronary syndrome can be quickly and safely discharged or admitted from the Emergency Department. The investigators hypothesize that intro...
What is the current status of trial NCT03590535?
This trial is currently completed. The enrollment target is 1,949 participants. The study started on 2018-09-24. Estimated completion is 2020-06-07.
What conditions does trial NCT03590535 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT03590535?
The interventions under investigation include: 4th Gen cTnT (DIAGNOSTIC_TEST), 5th Gen cTnT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03590535?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03590535 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03590535's enrollment target sits among peer trials
1,949 12th of 40 higher than 29 of 40 other Acute Coronary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
-
Positive Emotions Following Acute Cardiac Events
RECRUITING · NA
-
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
RECRUITING
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
A Prospective Research Investigation of Ischemia Using MCG
RECRUITING
-
AngelMed Guardian® System PMA Post Approval Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI